Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1445-1454

  Lim, Li Ying ^a   Koh, Pei Yin ^a   Somani, Sukrut ^a   Al Robaian, Majed ^a   Karim, Reatul ^a   Yean, Yi Lyn ^a   Mitchell, Jennifer ^a   Tate, Rothwelle J ^a   Edrada Ebel, RuAngelie ^a   Blatchford, David R ^a   Mullin, Margaret ^b   Dufès, Christine ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer therapy; Dendrimer; Gene delivery; Lactoferricin; Lactoferrin

Indexed keywords

ANIMALS; CELLS; DENDRIMERS; DISEASES; FUNCTIONAL POLYMERS; GENE EXPRESSION; GENE TRANSFER; GENES; ONCOLOGY; TUMORS;

CANCER THERAPY; CHEMOTHERAPEUTIC AGENTS; GENE DELIVERY; GENE DELIVERY SYSTEMS; INTRAVENOUS ADMINISTRATION; LACTOFERRICIN; LACTOFERRIN; THERAPEUTIC EFFICACY;

GENE THERAPY;

DENDRIMER; LACTOFERRICIN; LACTOFERRIN; LACTOFERRICIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR REGRESSION; ANIMAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; TUMOR CELL LINE;

ANIMALIA;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CELL LINE, TUMOR; DENDRIMERS; HUMANS; LACTOFERRIN; NEOPLASMS;

EID: 84937153488     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.04.006     Document Type: Article

References (29)

1. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat Biotechnol 2000, 18:33-37.
2. Li S.D., Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007, 123:181-183.
3. Dufès C., Uchegbu I.F., Schätzlein A.G. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005, 57:2177-2202.
4. Koppu S., Oh Y.J., Edrada-Ebel R., Blatchford D.R., Tetley L., Tate R.J., et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release 2010, 143:215-221.
5. Zhou Y., Zeng Z., Zhang W., Xiong W., Wu M., Tan Y., et al. Lactotransferrin: a candidate tumor suppressor- Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 2008, 123:2065-2072.
6. Gifford J.L., Hunter H.N., Vogel H.J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005, 62:2588-2598.
7. Eliassen L.T., Berge G., SveinbjØrnsson B., Svendsen J.S., Vorland L.H., Rekdal Ø. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002, 22:2703-2710.
8. Yoo Y.C., Watanabe S., Watanabe R., Hata K., Shimazaki K., Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 1997, 88:184-190.
9. Aldawsari H., Sundara Raj B., Edrada-Ebel R., Blatchford D.R., Tate R.J., Tetley L., et al. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polyethylenimine polyplex. Nanomedicine 2011, 7:815-823.
10. Aldawsari H., Edrada-Ebel R., Blatchford D.R., Tate R.J., Tetley L., Dufès C. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex. Biomaterials 2011, 32:5889-5899.
11. Lemarié F., Croft D.R., Tate R.J., Ryan K.M., Dufès C. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. Biomaterials 2012, 33:2701-2709.
12. Al Robaian M., Chiam K.Y., Blatchford D.R., Dufès C. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes encoding TNF-α, TRAIL and interleukin-12 on prostate carcinomas. Nanomedicine (Lond) 2014, 9:421-434.
13. Zinselmeyer B.H., Beggbie N., Uchegbu I.F., Schätzlein A.G. Quantification of beta-galactosidase activity after non-viral transfection in vivo. J Control Release 2003, 91:201-208.
14. Zinselmeyer B.H., Mackay S.P., Schätzlein A.G., Uchegbu I.F. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002, 19:960-967.
15. Eisenauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
16. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
17. Mahato R.I., Smith L.C., Rolland A. Pharmaceutical perspectives of nonviral gene therapy. Adv Genet 1999, 41:95-156.
18. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 2001, 12:1005-1011.
19. Visser C.C., Stevanović S., Voorwinder H., Gaillard P.J., Crommelin D.J., Danhof M., et al. Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target 2004, 12:145-150.
20. Kim H.R., Gil S., Andrieux K., Nicolas V., Appel M., Chacun H., et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007, 64:356-364.
21. Liu J., Shapiro J.I. Endocytosis and signal transduction: basic science update. Biol Res Nurs 2003, 5:117-128.
22. Wei M., Xu Y., Zou Q., Tu L., Tang C., Xu T., et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci 2012, 46:131-141.
23. Chen H., Qin Y., Zhang Q., Jiang W., Tang L., Liu J., et al. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci 2011, 44:164-173.
24. Elfinger M., Maucksch C., Rudolph C. Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 2007, 28:3448-3455.
25. Wang J., Li Q., Li K., Ou Y., Han Z., Gao D., et al. Effects of adenovirus vectors mediated human lactoferrin cDNA on mice bearing EMT6 breast carcinoma. Pharmazie 2011, 66:704-709.
26. Wang J., Li Q., Ou Y., Han Z., Li K., Wang P., et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 2011, 34:987-995.
27. Wang J., Li Q., Ou Y., Li K., Han Z., Wang P., et al. Recombination adenovirus-mediated human lactoferrin cDNA inhibits the growth of human MCF-7 breast cancer cells. J Pharm Pharmacol 2012, 64:457-463.
28. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J Control Release 1992, 19:315-324.
29. Mocellin S., Rossi C.R., Pilati P., Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005, 16:35-53.